<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36156117</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1537-6591</ISSN><JournalIssue CitedMedium="Internet"><Volume>76</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</Title><ISOAbbreviation>Clin Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Remdesivir Resistance in Transplant Recipients With Persistent Coronavirus Disease 2019.</ArticleTitle><Pagination><StartPage>342</StartPage><EndPage>345</EndPage><MedlinePgn>342-345</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">ciac769</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/cid/ciac769</ELocationID><Abstract><AbstractText>New mutations conferring resistance to SARS-CoV-2 therapeutics have important clinical implications. We describe the first cases of an independently acquired V792I RNA-dependent RNA polymerase mutation developing in renal transplant recipients after remdesivir exposure. Our work underscores the need for augmented efforts to identify concerning mutations and address their clinical implications.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hogan</LastName><ForeName>John I</ForeName><Initials>JI</Initials><AffiliationInfo><Affiliation>Department of Medicine, NYU Long Island School of Medicine, Mineola, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duerr</LastName><ForeName>Ralf</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Microbiology, NYU Grossman School of Medicine, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dimartino</LastName><ForeName>Dacia</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Genome Technology Center, NYU Langone Health, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marier</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Genome Technology Center, NYU Langone Health, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hochman</LastName><ForeName>Sarah E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Department of Medicine, NYU Grossman School of Medicine, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mehta</LastName><ForeName>Sapna</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine, NYU Grossman School of Medicine, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Guiqing</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Medicine, NYU Grossman School of Medicine, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heguy</LastName><ForeName>Adriana</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-2836-6683</Identifier><AffiliationInfo><Affiliation>Genome Technology Center, NYU Langone Health, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, NYU Grossman School of Medicine, New York, New York, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 CA016087</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Infect Dis</MedlineTA><NlmUniqueID>9203213</NlmUniqueID><ISSNLinking>1058-4838</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>3QKI37EEHE</RegistryNumber><NameOfSubstance UI="C000606551">remdesivir</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>Res Sq. 2022 Jun 29:rs.3.rs-1800050. doi: 10.21203/rs.3.rs-1800050/v1.</RefSource><PMID Version="1">35794888</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066027" MajorTopicYN="N">Transplant Recipients</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="N">COVID-19 Drug Treatment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antiviral resistance</Keyword><Keyword MajorTopicYN="N">immunocompromise</Keyword><Keyword MajorTopicYN="N">remdesivir</Keyword><Keyword MajorTopicYN="N">severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)</Keyword><Keyword MajorTopicYN="N">solid-organ transplant</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>26</Day><Hour>16</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>9</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36156117</ArticleId><ArticleId IdType="pmc">PMC9619446</ArticleId><ArticleId IdType="doi">10.1093/cid/ciac769</ArticleId><ArticleId IdType="pii">6717535</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Saharia KK, Anjan S, Streit J, et al. . Clinical characteristics of COVID-19 in solid organ transplant recipients following COVID-19 vaccination: a multicenter case series. Transpl Infect Dis 2022; 24:e13774.</Citation><ArticleIdList><ArticleId IdType="pubmed">34905269</ArticleId></ArticleIdList></Reference><Reference><Citation>Manothummetha K, Chuleerarux N, Sanguankeo A, et al. . Immunogenicity and risk factors associated with poor humoral immune response of SARS-CoV-2 vaccines in recipients of solid organ transplant: a systematic review and meta-analysis. JAMA Netw Open 2022; 5:e226822.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9006106</ArticleId><ArticleId IdType="pubmed">35412626</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens LJ, Pruijssers AJ, Lee HW, et al. . Mutations in the SARS-CoV-2 RNA dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms. Sci Transl Med 2022; 14:eabo0718.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9097878</ArticleId><ArticleId IdType="pubmed">35482820</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandhi S, Klein J, Robertson AJ, et al. . De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report. Nat Commun 2022; 13:1547.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8930970</ArticleId><ArticleId IdType="pubmed">35301314</ArticleId></ArticleIdList></Reference><Reference><Citation>Clerico M, Dogliotti I, Calcagno A, et al. . COVID-19 in a post-transplant heart recipient who developed aggressive lymphoma: a biphasic course during rituximab treatment. Hemasphere 2021; 5:e592.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8196101</ArticleId><ArticleId IdType="pubmed">34131632</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen KM, Bates BA, Rashidi ES, et al. . Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative. Lancet Rheumatol 2022; 4:e33&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8592562</ArticleId><ArticleId IdType="pubmed">34806036</ArticleId></ArticleIdList></Reference><Reference><Citation>Moeller NH, Shi K, Demir O, et al. . Structure and dynamics of SARS-CoV-2 proofreading exoribonuclease ExoN. Proc Natl Acad Sci USA 2022; 119:e2106379119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8892293</ArticleId><ArticleId IdType="pubmed">35165203</ArticleId></ArticleIdList></Reference><Reference><Citation>
Global Initiative on Sharing Avian Influenza Database (GISAID) . Home page. 2022. Available at: https://www.gisaid.org/(Accessed July 2022).</Citation></Reference><Reference><Citation>Wilkinson SA, Richter A, Casey A, et al. . Recurrent SARS-CoV-2 mutations in immunodeficient patients. medRxiv [Preprint]. [cited 2 March 2022]. Available at: 10.1101/2022.03.02.22271697.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.03.02.22271697</ArticleId><ArticleId IdType="pmc">PMC9384748</ArticleId><ArticleId IdType="pubmed">35996593</ArticleId></ArticleIdList></Reference><Reference><Citation>Checkmahomed L, Pont VD, Riola NC, et al. . In vitro selection of remdesivir-resistant SARS-CoV-2 demonstrates high barrier to resistance. bioRxiv [Preprint]. [cited 12 February 2022]. Available at:10.1101/2022.02.07.479493.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.02.07.479493</ArticleId><ArticleId IdType="pmc">PMC9295571</ArticleId><ArticleId IdType="pubmed">35708323</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockett R, Basile K, Maddocks S, et al. . Resistance mutations in SARS-CoV-2 delta variant after sotrovimab use. N Engl J Med 2022; 386:1477&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8929376</ArticleId><ArticleId IdType="pubmed">35263515</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennehy JJ, Gupta RK, Hanage WP, Johnson MC, Peacock TP. Where is the next SARS-CoV-2 variant of concern? Lancet 2022; 399:1938&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9119661</ArticleId><ArticleId IdType="pubmed">35598619</ArticleId></ArticleIdList></Reference><Reference><Citation>Burki T. The origin of SARS-CoV-2 variants of concern. Lancet Infect Dis 2022; 22:174&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9760347</ArticleId><ArticleId IdType="pubmed">35033232</ArticleId></ArticleIdList></Reference><Reference><Citation>Duerr R, Dimartino D, Marier C, et al. . Dominance of alpha and iota variants in SARS-CoV-2 vaccine breakthrough infections in New York City. J Clin Invest 2021; 131:e152702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8439605</ArticleId><ArticleId IdType="pubmed">34375308</ArticleId></ArticleIdList></Reference><Reference><Citation>Goddard TD, Huang CC, Meng EC, et al. . UCSF ChimeraX: meeting modern challenges in visualization and analysis. Protein Sci 2018; 27:14&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5734306</ArticleId><ArticleId IdType="pubmed">28710774</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>